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T ranscatheter aortic valve replacement (TAVR)is a management choice for patients withsevere symptomatic aortic stenosis (AS)
who are deemed poor operative candidates. The
decision to proceed with TAVR is by no means
simple; it requires the evaluation of considerations
such as the team performing the procedures, de-
vice suitability, and short-term and long-term out-
comes. In the 2012 ACCF/AATS/SCAI/STS Expert
Consensus Document on Transcatheter Aortic Valve
Replacement (1), the authors described the com-
plexity of the device and the need for a team approach
and monitoring of outcomes. Given the potential for
complications in this delicate population, careful pa-
tient selection is required; ultimately, the procedure
is offered with the understanding that surgery is pro-
hibitively risky. The inherent risks of TAVR in the
population deemed inoperable is balanced against
the observation that inoperable patients with severe
AS who do not receive a valve replacement face a
50% incidence rate of 1-year mortality (2).
When offering any new technology, it is critical
to evaluate any unforeseen or device-speciﬁc com-
plications that can arise. TAVR is associated with
a number of clear risks, including vascular compli-
cations, bleeding, stroke, perivalvular leaks, and
death. It is estimated that nearly one-third of
patients with severe AS who could beneﬁt from the
hemodynamic correction of aortic valve placement
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for TAVR (3).In this issue of the Journal, Siontis et al. (4) focus
on one particular outcome: the need for placement
of a permanent pacemaker after TAVR. For compar-
ative purposes, following surgical aortic valve re-
placement (AVR) in high-risk patients (with a mean
Society of Thoracic Surgeons [STS] predicted risk
of mortality of 16.3%), complications include the
need for a new permanent pacemaker in 5% of
patients (5). In the surgical population, a number of
predictors indicating the need for a permanent
pacemaker after AVR have been noted, including
aortic insufﬁciency, pulmonary hypertension, and
prior myocardial infarction. Proposed mechanisms
for the increased risk include the effects of stretch
associated with aortic insufﬁciency or pulmonary
hypertension and prior ischemic injury to the con-
duction system (6). An alternate explanation for the
increased risk of a pacemaker in those with pre-
operative aortic insufﬁciency may be related to the
size of the aortic annulus and the larger size of the
implanted prosthetic valve (7). Little is known about
the long-term impact of pacemaker implantation in
the surgical population.
Two commercially available valves are considered
in the report by Siontis et al. (4): the Edwards Sapien
valve (ESV) (Edwards Lifesciences, Inc., Irvine,
California) and the Medtronic CoreValve Revalving
System (MCRS) (Medtronic, Inc., Minneapolis, Min-
nesota). These 2 valves are signiﬁcantly different in
construction. The ESV is composed of a trileaﬂet
bovine pericardial valve that is mounted on a balloon-
expandable cobalt chromium alloy stent. In the
United States, it is available in 23- and 26-mm sizes; in
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MCRS is comprised of porcine pericardial tissue leaf-
lets mounted on a self-expanding nitinol frame. The
sizes available are 26 mm, 29 mm, and 31 mm. The
overall proﬁle of the MCRS is larger, and the nitinol
frame extends further down into the left ventricular
outﬂow tract. At the time of data extraction for the
report by Siontis et al. (4), only the ESV was approved
by the Food and Drug Administration in the United
States but both valves were available in Europe. The
MCRS now has gained Food and Drug Administration
approval in the United States, and implantation has
begun in selected centers.
The overall rate of requirement of a permanent
pacemaker after TAVR (regardless of which valve was
used) was 17% (4), as compared with the 5% rate re-
ported with AVR (5). The rate of requirement of a
permanent pacemaker was higher in patients treated
with the MCRS (median of 28%) than with the ESV
(6%). Similar to the surgical experience, Siontis et al.
(4) identiﬁed several parameters that indicate a
high risk of requirement of a permanent pacemaker.
On the basis of their wide literature search, they were
able to identify an increased risk irrespective of
valve type in male patients; those with baseline
ﬁrst-degree atrioventricular (AV) block, left anterior
hemiblock, or right bundle branch block; and those
who developed periprocedural AV block. Use of the
MCRS was associated with a 2.5-fold risk of require-
ment of a pacemaker.
Some light was shed on these observations by a
recent study of the conduction system, which was
prompted by observations of the risk of heart block
in patients undergoing TAVR. In an anatomic study,
Kawashima and Sato (8) reported that the AV node
and left bundle branch are located more anteriorly,
distally, and cranially and closer to the aortic root
than previously believed. Thus, it is not surprising
that patients with pre-existing right bundle branch
block or ﬁrst-degree AV block would be at greater risk
for heart block with device manipulation in the left
ventricular outﬂow. It also would be reasonable to
anticipate a fairly high prevalence of pre-existing
conduction abnormalities in the type of patient who
would be a candidate for TAVR (i.e., an older popu-
lation with calciﬁc AS).
An interesting dynamic exists between the type
of valve and theoretical concerns regarding heart
block after TAVR. Similar to surgery, there can be
improvement in conduction after initial disturbances
following TAVR, presumably related to reversible
procedural-related trauma to the conduction system
(2,9). As such, when the patient is hemodynamically
stable or has a functional temporary pacemaker,some delay before committing to a permanent pace-
maker may be appropriate. However, the duration of
“watchful waiting” is not deﬁned either in the report
by Siontis et al. (4) or in the surgical literature. On
the other hand, the self-expanding MCRS may not
fully expand for 7 to 10 days (10). Therefore, it is
conceivable that the full extent of potential risk may
not be immediately apparent at the time of TAVR. At
this juncture, there are no concrete recommendations
for indications for pacemaker implantation or timing
of implantation after TAVR. Future data from TAVR
centers and from pacemaker surveillance clinics may
be elucidating.
The higher risk of pacemaker implantation in
men is also an interesting observation, and it is not
immediately apparent whether this is due to implan-
tation of larger valves, with larger proﬁles leading
to greater risk of mechanical trauma versus variations
in anatomic factors (i.e., more advanced disease,
greater degree of calciﬁcation).
When considering future applications and the
development of prosthetic valves for percutaneous
applications, the observations from the current
study may point to important characteristics such
as lower proﬁle and shorter height. Alternatively,
modifying implantation techniques could potentially
reduce the risk of pacemaker implantation (11). In
addition, the long-term consequences of pacemaker
implantation and type of pacemaker devices used
in these patients need to be evaluated. There are
data showing that QRS duration following TAVR may
be a predictor of outcomes. In a single-center pro-
spective study of patients post-TAVR, those with a
QRS duration of >150 ms had signiﬁcantly higher
all-cause mortality than did those with a QRS
duration of #120 ms (12). One meta-analysis of the
impact of pacemaker implantation after TAVR
showed no impact on mortality in patients receiving
new pacemaker implants after TAVR, but there was
worsening of heart failure and prolongation of hos-
pital stay (13).
These data underscore the importance of knowing
the patient characteristics that confer risks for pace-
maker implantation post-TAVR, as well described by
Siontis et al. (4), and thereby taking steps to monitor
patients appropriately. Furthermore, procedure
modiﬁcations to potentially reduce risk and reﬁne-
ment of percutaneous valve types to minimize
trauma to the conduction system are anticipated.
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